Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial
CONCLUSIONS: Abatacept is very efficacious to treat both retinal vasculitis and choroiditis in patients with BU and is well tolerated. BCVA and CRT are inadequate to monitor disease activity. On the other hand, CCT is a promising non-invasive tool to detect treatment response in early active BU and dual FA-ICGA Score is very helpful to evaluate retinal vasculitis and choroiditis quantitatively.TRIAL REGISTRATION NUMBER: NCT03871361.PMID:36585127 | DOI:10.1136/bjo-2022-321585
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: P P Schauwvlieghe Joachim Van Calster Carl Peter Herbort Philippe A Kestelyn Kurt de Vlam Source Type: research
More News: Abatacept | Angiography | Autoimmune Disease | Opthalmology | Orencia | UK Health | Vasculitis | Vitamin A